TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02255149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone/Mesh
Description: A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
Study: NCT03167606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile
Description: Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile
Description: Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
Study: NCT04067739

Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study

Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study
Study: NCT04423380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH3051 capsule treatment
Description: Starting dose 20mg,oral administered twice daily.If tolerated subsequent cohorts will test increasing doses (40mg,60mg,80mg,100mg) of SH3051.
Study: NCT01326663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication Trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medication Trial
Study: NCT06451653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men in Maternity Health (MiM) Intervention
Description: The six-month MiM education program focused on maternal health education for male partners of pregnant women in the intervention area. Assigned midwives offered two-hour-long, face-to-face health education and discussion sessions at five selected health centres every second and fourth Sunday, respectively, to accommodate participants' work schedules. Attendance consistently remained high at 80% of participants every month, with home visits for absentees to provide health education.
Study: NCT03069976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Flagyl x 14 days.
Study: NCT01693809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study: NCT04146805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409
Description: For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo
Description: Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
Study: NCT00354419

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study: NCT02959164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level
Study: NCT00354419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Undergo transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC
Study: NCT04268797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR rTMS
Description: high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: SHAM HF rTMS coil once daily x 20 days
Study: NCT02959164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1\*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~\*Starting Dose Level
Study: NCT02516735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-scan with magnification

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopy
Study: NCT03178695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous PRP injection into human ovarian tissue
Description: Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
Study: NCT02786524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Symptom Management and Supportive Care
Description: Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
Study: NCT01525173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% brimonidine tartrate ophthalmic solution
Description: 1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.01% bimatoprost ophthalmic solution
Description: 1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.01% bimatoprost ophthalmic solution
Description: 1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% hypromellose lubricant eye drops
Description: 1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% ophthalmic solution
Description: 1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% ophthalmic solution
Description: 1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
Study: NCT03706222

Intervention type: DRUG
Intervention: elbasvir/grazoprevir
Description: Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
Study: NCT02117427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: Erythropoietin secreted by TARGTEPO transduced with MDGN201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: Erythropoietin secreted by TARGTEPO transduced with MDGN201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: Erythropoietin secreted by TARGTEPO transduced with MDGN201
Study: NCT01662960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: A home-based therapy involving mirrored visual feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Divider therapy
Description: A home-based therapy involving removed visual feedback.
Study: NCT01503658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel+Aspirin
Description: Clopidogrel 75 mg, Aspirin 100 mg
Study: NCT00898508

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: mutation analysis

Intervention type: GENETIC
Intervention: proteomic profiling

Intervention type: GENETIC
Intervention: proteomic profiling

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction

Intervention type: OTHER
Intervention: fluorescent antibody technique

Intervention type: OTHER
Intervention: fluorescent antibody technique

Intervention type: OTHER
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Intervention: liquid chromatography

Intervention type: OTHER
Intervention: liquid chromatography

Intervention type: OTHER
Intervention: mass spectrometry

Intervention type: OTHER
Intervention: mass spectrometry

Intervention type: OTHER
Intervention: medical chart review

Intervention type: OTHER
Intervention: medical chart review

Intervention type: PROCEDURE
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Study: NCT02382224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Worry Exposure for GAD
Description: WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 12-week Waitlist
Description: Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
Study: NCT04643691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg and Spironolactone 25 mg pillules oral use
Description: Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
Study: NCT02316054

Intervention type: DEVICE
Intervention: MPHI
Description: addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
Study: NCT00989053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: 10 mg/d for a duration of 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 1 pill per day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill per day for 8 weeks
Study: NCT00508651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-560
Description: MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson\^TM luer slip tip syringes. Each 0.2 mL dose contained 10\^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was a frozen preparation filled into Becton Dickinson\^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
Study: NCT01104181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HC2 collection kit with a swab or brush
Description: We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
Study: NCT02203539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to normal light
Description: exposure for 60 minutes in duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to bright light
Description: exposure to bright light for 60 minutes of duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to blue-enriched light
Description: exposure to blue-enriched light for 60 minutes of duration
Study: NCT04579393

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
Study: NCT03204851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Healing
Description: Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Healing
Description: Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Healing
Description: Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Healing
Description: Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
Study: NCT02016235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphorus Supplement
Description: 250 mg po qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphorus Supplement
Description: 250 mg po qid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: Baseline blood and urine measurements only
Study: NCT03882801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of gefapixant (MK-7264) QHS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
Study: NCT01085929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Aspiration
Description: Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
Study: NCT02766673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate
Description: Subjects will receive a dose of study medication every 4 hours for 24 total hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate
Description: Subjects will receive a dose of study medication every 4 hours for 24 total hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Subjects will receive a dose of study medication every 4 hours for 24 total hours
Study: NCT02360774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
Study: NCT00921297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Cataract Surgery
Description: Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
Study: NCT03268590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Persons will undergo MRI, EEG, and complete computerized cognitive testing in baseline room air. Persons will then breathe 100% pure oxygen and undergo MRI, EEG, and complete computerized cognitive testing. Persons will serve as their own controls.
Study: NCT00531011

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V® Everolimus Eluting Coronary Stent System
Description: Coronary artery placement of a drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
Description: Coronary artery placement of a drug-eluting stent
Study: NCT02139982

Intervention type: PROCEDURE
Group type: OTHER
Intervention: specific nerve block
Description: specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region

Intervention type: PROCEDURE
Group type: OTHER
Intervention: specific nerve block
Description: specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region

Intervention type: PROCEDURE
Group type: OTHER
Intervention: specific nerve block
Description: specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region

Intervention type: PROCEDURE
Group type: OTHER
Intervention: specific nerve block
Description: specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Different concentration of ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Different concentration of ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Different concentration of ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Different concentration of ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Different concentration of ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Different concentration of ropivacaine
Study: NCT01064583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cocoa
Description: dissolved in water twice-daily intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cocoa
Description: dissolved in water twice-daily intervention
Study: NCT02971891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS006 (Furosemide) Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Study: NCT02929342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]-Pitolisant
Study: NCT05153278

Intervention type: BIOLOGICAL
Intervention: Packed red blood cells
Description: Standard treatment for iron deficiency anemia (control)

Intervention type: DRUG
Intervention: Intravenous drug
Description: Experimental treatment for iron deficiency treatment
Study: NCT02774343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Cognitive-behavioral therapy 1 hour per week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Cognitive-behavioral therapy 1 hour per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Prize-based contingency management for attendance

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: Prize-based contingency management for attendance
Study: NCT03477461

Intervention type: DRUG
Intervention: terlipressin
Description: a continuous infusion of terlipressin (0.4 mg/kg/h) was initiated
Study: NCT06273189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional
Description: In conventional group, contralateral side mandibular osteotomies were performed with Lindeman and round bur (Karl Storz, Tuttlingen, Germany)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scalpel
Description: In ultrasonic device group, osteotomies one side of the mandible were performed unilaterally using an ultrasonic bone scalpel (BoneScalpel; Misonix, Farmingdale, NY) with a serrated standard blade
Study: NCT01705470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo normal saline
Study: NCT03692988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
Study: NCT02173535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon test contact lens Variant AP
Description: Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon test contact lens Variant AP
Description: Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon test contact lens Variant AP
Description: Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon test contact lens Variant AP
Description: Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
Study: NCT03882801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
Study: NCT04329052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adventure-based training with health educational talk
Description: Participants need to attend an adventure-based training with various experiential learning activities with a health educational talk on mental health.
Study: NCT04005547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder
Description: Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication \*Bring your Trusted Adult\* Session 6 - Let's Talk About Growing Up